Aaron From, MD
Interventional Cardiology · Des Moines, IANPI 1255319596
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $613 of the $793 with a category attached, or 77.3%. 11 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 25.9% of the total. Reporting peaked in 2023 at $244 and has fallen 80.6% since, to $47 in 2025. That places this record below the midpoint for interventional cardiology clinicians in IA, where the typical reported total is $3,872.
Across 29 payments — averaging $27.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$205
- Astellas Pharma US Inc$180
- Shockwave Medical, Inc$176
- Abbott$88
- Novartis$31
- Boehringer Ingelheim$21
- plus $92 from 5 others
What the payments were for
- Food & beverage$61377%
- Education$18023%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $205 |
| Astellas Pharma US Inc | 2 | $180 |
| Shockwave Medical, Inc | 4 | $176 |
| Abbott | 5 | $88 |
| Novartis | 1 | $31 |
| Boehringer Ingelheim | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Penumbra, Inc. | 1 | $21 |
| Teleflex LLC | 1 | $19 |
| Edwards Lifesciences | 1 | $17 |
| Livanova USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$793 in reported general payments places this provider in the 15th percentile of 64 interventional cardiology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 246 | $205,860 |
| XareltoRivaroxaban | 44 | $48,728 |
| BrilintaTicagrelor | 72 | $42,409 |
| Repatha SureclickEvolocumab | 23 | $12,559 |
| Metoprolol Succinate | 310 | $3,544 |
| CrestorRosuvastatin Calcium | 13 | $2,785 |
| Prasugrel Hcl | 25 | $2,188 |
| Atorvastatin Calcium | 320 | $2,031 |
| Rosuvastatin Calcium | 158 | $1,759 |
| ClopidogrelClopidogrel Bisulfate | 195 | $1,566 |
| Bumetanide | 52 | $1,562 |
| Ezetimibe | 23 | $1,498 |
| Ranolazine ErRanolazine | 21 | $1,088 |
| Furosemide | 247 | $1,035 |
| Potassium Chloride | 67 | $937 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Des Moines
- Atul ChawlaDes Moines$78K
- David McAllisterDes Moines$55K
- Daniel ShivapourDes Moines$54K
- Abdulrahman AbdulbakiDes Moines$43K
- Musab AlqasrawiDes Moines$6K
- Ravinder DerveshDes Moines$3K
- Hamza OglatDes Moines$924
- Martin AronowDes Moines$232
- Nicolas ShammasDavenport$808K
- Eric DippelDavenport$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.